Legacy Bridge’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Bridge’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24	Closed	-$10.9K	–	468
2025 Q4	$10.9K	Buy	+24	New	+$10.3K	﹤0.01%	301
2025 Q3	–	Sell	-2,332	Closed	-$1.04M	–	317
2025 Q2	$1.04M	Hold	2,332	–	–	0.49%	73
2025 Q1	$1.13M	Buy	2,332 +2,121	+1,005%	+$988K	0.63%	62
2024 Q4	$85K	Hold	211	–	–	0.04%	167
2024 Q3	$98.1K	Hold	211	–	–	0.05%	165
2024 Q2	$98.9K	Buy	211 +100	+90%	+$43.4K	0.06%	161
2024 Q1	$46.4K	Hold	111	–	–	0.03%	200
2023 Q4	$45.2K	Buy	+111	New	+$41K	0.03%	195

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Legacy Bridge's VRTX Position: Q1 2026 in Review

Legacy Bridge sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 24 shares — an estimated $10.9K sold.

Legacy Bridge first reported a position in VRTX in Q4 2023 and held it in 8 quarters. The position peaked at $1.13M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Legacy Bridge reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Legacy Bridge sold 24 Vertex Pharmaceuticals shares in Q1 2026, an estimated $10.9K.
Legacy Bridge first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Legacy Bridge's Vertex Pharmaceuticals position peaked at $1.13M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Legacy Bridge's 13F filing for Q1 2026, filed 14 May 2026.